Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
- 1 February 2003
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 48 (2) , 201-206
- https://doi.org/10.1067/mjd.2003.44
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Cutaneous Reactions to STI571New England Journal of Medicine, 2001
- Acute Generalized Exanthematous Pustulosis Associated with STI571 in a Patient with Chronic Myeloid LeukemiaDermatology, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990